

ESMO-EANM Advanced Course on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology

PROGRAMME

**ESMO
ADVANCED COURSE**

**ESSEN GERMANY
22-23 MAY 2024**

Co-Chairs

Ken Herrmann, Germany

Aurelius G. Omlin, Switzerland

ESMO-EANM ADVANCED COURSE PROGRAMME

DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF NUCLEAR MEDICINE IN ONCOLOGY

Essen, Germany
22-23 May 2024

CO-CHAIRS Ken Herrmann, Germany
Aurelius G. Omlin, Switzerland

SPEAKERS Eva Compérat, Austria
Désirée Deandreis, France
Wolfgang Fendler, Germany
Laura Graven, The Netherlands
Viktor Grünwald, Germany
Jolanta A. Krajewska, Poland
Michael Nader, Germany
Marianne E. Pavel, Germany

LEARNING OBJECTIVES

- To get an updated analysis of the diagnostic and therapeutic applications of nuclear medicine in oncology
- To provide a knowledge of principles of both nuclear medicine modalities and systemic oncologic therapies in advanced trainees and specialists in oncology and nuclear medicine
- To provide an educational framework for in-depth analysis of the combined diagnostic/therapeutic strategies (theranostics) in oncology and scientific interaction between oncology and nuclear medicine experts
- To foster interdisciplinary exchange and collaboration in both nuclear medicine imaging and nuclear medicine treatment applications

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 22 May 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and learning objectives introduction
Ken Herrmann, DE and Aurelius G. Omlin, CH

09:10-10:50 **Session 1 - Introduction to theranostics and systemic therapies** **Chairs: Désirée Deandreis, FR and Jolanta A. Krajewska, PL**

20' Definitions and therapeutic concepts of therapeutic radionuclides
Ken Herrmann, DE

20' Regulatory challenges in the development of theranostics
Michael Nader, DE

20' Radioiodine therapy in thyroid cancer
Désirée Deandreis, FR

20' Landscape of systemic therapies for thyroid malignancies
Jolanta A. Krajewska, PL

20' Discussion

10:50-11:20 Coffee break

11:20-12:20 **Workshop session**

Workshop session where clinical cases are presented by speakers with interactive questions and discussion with the audience

60' Workshop time

Workshop 1 Thyroid malignancies
Désirée Deandreis, FR and Jolanta A. Krajewska, PL

12:20-13:20 Lunch

13:20-14:40 **Session 2 - NETs as role model for theranostics** **Chairs: Ken Herrmann, DE and Marianne E. Pavel, DE**

20' Overview NET: Epidemiology, disease specific characteristics and challenges
Laura Graven, NL

20' PRRT in NET: What is the standard?
Wolfgang Fendler, DE

20' Systemic therapies for NETs (other than PRRT)
Marianne E. Pavel, DE

20' Discussion

14:40-15:10 Coffee break

15:10-16:55	Session 3 - Expanding theranostics to prostate cancer Chairs: Laura Graven, NL and Aurelius G. Omlin, CH
20'	Biology in advanced prostate cancer with a special focus on PSMA across the disease spectrum (primary tumour, upregulation with AR targeted therapies, heterogeneity, etc) Eva Compérat, AT
25'	Treatment landscape in advanced prostate cancer Aurelius G. Omlin, CH
25'	How to make best use of PSMA RLT in advanced prostate cancer – Status May 2024 Ken Herrmann, DE
15'	Future of PSMA RLT outside of prostate cancer Viktor Grünwald, DE
20'	Discussion and Conclusion of Day 1
19:30	Networking Dinner

Thursday, 23 May 2024

9:00-12:30	Workshop sessions Workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the audience 60' Workshop time
Workshop 2	How to build and run a theranostic unit Laura Graven, NL and Ken Herrmann, DE
Workshop 3	NET theranostics Wolfgang Fendler, DE and Marianne E. Pavel, DE
11:00-11:30	Coffee break
Workshop 4	Prostate cancer RLT: Selection and monitoring of patients on treatment Ken Herrmann, DE and Aurelius G. Omlin, CH
12:30-13:00	Conclusion & farewell Ken Herrmann, DE and Aurelius G. Omlin, CH
13:00-14:00	Lunch